Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLN-0052, A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC®)

NCT04050865 is registered in ClinicalTrials.gov with Ocular Therapeutix, Inc. as lead sponsor.

NCT NCT04050865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04050865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLN-0052, A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC®)
Lead sponsor
Ocular Therapeutix, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2019
Completion date
February 28, 2020
Enrollment
96 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

allergic conjunctivitis